Company profile: Ambrx
1.1 - Company Overview
Company description
- Provider of an expanded genetic code technology platform to discover and develop Engineered Precision Biologics, including next-generation ADCs, bispecific antibodies, targeted immuno-oncology therapies, novel cytokines and long-acting therapeutics; with clinical programs ARX788 for HER2-positive breast cancer and ARX517 for advanced prostate cancer, and partnerships to advance ADC oncology programs.
Products and services
- Expanded Genetic Code Technology Platform: Custom-engineered technology incorporating synthetic amino acids into proteins for site-specific conjugation, enhancing biologic drug stability and efficacy and enabling ADCs, bispecifics, targeted immuno-oncology therapies, novel cytokines, and long-acting therapeutics
- ARX788: Site-specific antibody-drug conjugate targeting HER2-positive breast cancer, currently in clinical development, architected for precise conjugation and targeted HER2 engagement in oncology applications
- ARX517: Clinical-stage antibody-drug conjugate targeting PSMA for the treatment of advanced prostate cancer, under clinical evaluation, engineered to deliver PSMA-directed therapy within ADC oncology programs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ambrx
Transgenomic
HQ: United States
Website
- Description: Provider of nucleic acid purification and analysis products for life sciences research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgenomic company profile →
Vanadis Diagnostics
HQ: Sweden
Website
- Description: Provider of a novel non-invasive prenatal testing (NIPT) solution in development based on digital analysis of cell-free DNA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanadis Diagnostics company profile →
Basepaws
HQ: United States
Website
- Description: Provider of at-home genetic testing for cats and dogs, including cat and dog DNA tests for breed analysis, trait information, and health risk markers; cat oral microbiome tests to screen for dental diseases; and whole genome sequencing for cats providing extensive genome data on health, traits, and breed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Basepaws company profile →
Mirati Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology, based at 9363 Towne Centre Dr, San Diego, CA, United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirati Therapeutics company profile →
Onkaido Therapeutics
HQ: United States
Website
- Description: Provider of research into messenger RNA therapeutics aimed at delivering novel oncology drugs to help patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onkaido Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ambrx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ambrx
2.2 - Growth funds investing in similar companies to Ambrx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ambrx
4.2 - Public trading comparable groups for Ambrx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →